REGENXBIO, Inc. (RGNX)
8.51
+0.16
(+1.92%)
USD |
NASDAQ |
Feb 13, 12:20
REGENXBIO Cash from Investing (Quarterly) : 42.29M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Omeros Corp. | -6.861M |
| Sarepta Therapeutics, Inc. | 232.40M |
| AbbVie, Inc. | -- |
| CytomX Therapeutics, Inc. | 0.439M |
| Krystal Biotech, Inc. | -4.286M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -55.96M |
| Cash from Financing (Quarterly) | -7.083M |
| Free Cash Flow | -106.28M |
| Free Cash Flow Per Share (Quarterly) | -1.092 |
| Free Cash Flow to Equity (Quarterly) | -52.90M |
| Free Cash Flow to Firm (Quarterly) | -43.28M |
| Free Cash Flow Yield | -24.47% |